Unlock stock picks and a broker-level newsfeed that powers Wall Street.
AFT Pharmaceuticals Limited (NZSE:AFT) insiders seem bullish, own 69% and have been buying more recently

In This Article:

Key Insights

  • AFT Pharmaceuticals' significant insider ownership suggests inherent interests in company's expansion

  • 69% of the company is held by a single shareholder (Hartley Atkinson)

  • Insiders have bought recently

If you want to know who really controls AFT Pharmaceuticals Limited (NZSE:AFT), then you'll have to look at the makeup of its share registry. The group holding the most number of shares in the company, around 69% to be precise, is individual insiders. Put another way, the group faces the maximum upside potential (or downside risk).

It's interesting to note that insiders have been buying shares recently. This could signal that stock prices could go up and insiders are here for it.

Let's delve deeper into each type of owner of AFT Pharmaceuticals, beginning with the chart below.

See our latest analysis for AFT Pharmaceuticals

ownership-breakdown
NZSE:AFT Ownership Breakdown February 20th 2025

What Does The Institutional Ownership Tell Us About AFT Pharmaceuticals?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

We can see that AFT Pharmaceuticals does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see AFT Pharmaceuticals' historic earnings and revenue below, but keep in mind there's always more to the story.

earnings-and-revenue-growth
NZSE:AFT Earnings and Revenue Growth February 20th 2025

We note that hedge funds don't have a meaningful investment in AFT Pharmaceuticals. Looking at our data, we can see that the largest shareholder is the CEO Hartley Atkinson with 69% of shares outstanding. This implies that they possess majority interests and have significant control over the company. Investors usually consider it a good sign when the company leadership has such a significant stake, as this is widely perceived to increase the chance that the management will act in the best interests of the company. For context, the second largest shareholder holds about 7.2% of the shares outstanding, followed by an ownership of 1.9% by the third-largest shareholder.

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.